Advice From the Frontlines of Pharma: Holistic Healthcare, The Opioid Crisis & Remote-Work in Pharma
32 minAudio
This episode of Pharma Sessions is much like a pharmacy - it has something for everyone. Tune in as we reflect on critical conversations hosted by Jonathan Kaskey, so far in the series. Whether it’s critical pathways into pharma careers, the opioid crisis, and work-life balance in the modern pharmaceutical industry, this recap explores it all. From transitioning into MSL roles to building diverse medical teams, guests share practical strategies for career advancement and cross-functional collaboration, offering valuable insights on medical affairs leadership, risk mitigation in pain management, and creating boundaries while working remotely. Think of this as the playbook for pharmaceutical professionals looking to navigate industry challenges and advance their careers. Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_04Hello, hello, and welcome back to Pharma Sessions. So I'm doing something a bit different for this episode. Had a lot of conversations with some really interesting people, and there's many more to come. But while I'm in a little bit of a lull, processing some recordings, waiting for interviews to be scheduled, I've actually gone back into the archives and pulled together some of my favorite moments from recent conversations. So today in this episode, we're weaving together clips from several different discussions to explore some of the key themes that have consistently emerged on the show.
SPEAKER_04From career navigation to proving cross-functional collaboration and even managing work-life balance. It's a collection of some really nice lessons and some real-world advice, as always, from the front lines of pharma. And if you're like me, a child of the 90s, you can certainly appreciate a good clip show. Hello, hello, and welcome to Pharma Sessions, a place for pharmaceutical leaders to come and learn from each other.
SPEAKER_04I'm your host, Jonathan Kaskey. Technology and market trends are bringing change at an ever accelerating rate, and no person, team, or company can afford to be left behind. Here, we dive into the strategies and tactics that our guests use to tackle these challenges and create new opportunities and how you can do the same in your own organization. So, first up is Adam Lateman, Director of Medical Affairs at Salic's Pharmaceuticals.
SPEAKER_04He'll discuss the challenges of recruiting physicians into pharma and explain the fundamental difference between being a quote consumer of information as an MSL and a producer of information as a medical director. Love this concept. I know that and from other people that I've spoken with in, say, pharmacy school, right? Actually, the interview I did right before speaking to you was with a woman who went to, I think it was Florida State for pharmacy school. Internship opportunities with industry pharma had a real presence on there as far as exposing them to different career paths.
SPEAKER_04Is that an opportunity that's missing at medical school?
SPEAKER_05Absolutely. It's not discussed at all in medical school. And it's even less discussed in residency.
SPEAKER_04If you were to try to say, hey, I'm I'm now building a field team, I want to try to build this diverse team, I mean, how do you even go about trying sourcing doctors, for example, or nurses? Let's stick on doctors, right? Because that's your experience.
SPEAKER_05So that's a really good question. And it's something that in field medical, I've been a part of different initiatives and cultivated that on my own from the ground floor with the intent to introduce physicians to industry. Now, there's two different ways that you could do it. Some of them have been more successful than others. One way that you could do it is you can have physicians or field medical do some sort of lecture series to residents about the disease state that they're responsible for, not necessarily speaking about the drug, but giving an overview of the disease state because they've been experts in that state for years.
SPEAKER_05They're in conversation with a lot of opinion leaders that often write the chapters of books that these residents are studying. So that's one way that you could do it. And that way has been moderately successful. The other way that you could do it is in medical school. And that has not been successful at all because you are firewalled as industry from getting into that medical school because the medical school's entire objective is to train individuals to pass their board exams, none of which has anything to do with industry.
SPEAKER_04Right. It's almost their version of what you were talking about about why not expose MSLs to broader things while you're diverting them from the core thing that they're measured against, right? And here anything else is getting them off of that. And probably, you know, they want to be able to brag about the various placements that they have for their for their residents as well. This is projection, right? But this is my role as a podcaster, is to sit here behind a microphone and talk about things.
SPEAKER_05It's interesting now because the acronym healthcare provider is not necessarily the same as physician. In other words, healthcare provider encompasses anybody that is involved in in the healthcare industry that is providing some form of healthcare, whether that be a pharmacist, whether that be a physician's assistant, whether that be a nurse practitioner or even a physician. In medical school, it's doctors. And they're only concerned about doctors because that's what they're trying to create.
SPEAKER_05So the idea of that and cultivation of that might be a little bit antiquated with regards to what is transpiring now with industry and the partnership and the whole machine that is healthcare.
SPEAKER_04This whole idea is I just find really interesting. Like you kind of had a dream team going at that MSL that you were describing. And it should be not impossible to recreate if people want to do that. I mean, there's enough industry-specific recruiters for MSL positions that you can sort of write your requirements and say, I'm looking to do XYZ. But it sounds like that's not really the mindset that most pharma companies have as they're building these out.
SPEAKER_05I would say at my current company, we have individuals with physician assistant backgrounds, farm Ds, MDs, etc. So it is multifaceted across the team. I would probably say that it's the most farm Ds, but again, they're extremely qualified and excellent at what they do as well.
SPEAKER_04And so we sort of cut your career journey off. This kind of wrapping up here, but you talked a lot about your time as an MSL. Why did you end up switching over, leaving field medical and becoming a medical director? Because I have two kids, six and three.
SPEAKER_05That's the short answer. Yeah, it's that's legit. The long answer is that at the time I back to my first company when I was doing those rotations and I was learning about it, I had met with an individual. I think he worked in clinical development at the time. And I referenced this statement earlier that has always resonated with me, which is to say that in field medical, you're a consumer of information. Your objective is to know anything and everything about the happenings going on in your field, externally outside of the company.
SPEAKER_05When you're a medical director, particularly internally, you're a producer of information. You become responsible for the strategy, the research correlated to the product that you're in support of. And that was something that always resonated with me. I wanted to have that opportunity to sort of carve the path of the products that I'm responsible for from a research and medical perspective. So an opportunity opened up at my company and I applied for it, and I was given the position.
SPEAKER_04Next, you'll hear from Amet and Soumie. And Amet, I apologize when we did the recording, I knew how to pronounce your last name. I don't anymore. My bad. Emmet's a field medical leader and shares her personal journey of breaking into the industry, starting from a pharmacist role, detailing how she strategically mapped her existing skills to land a project management job before making the move to become an MSL.
SPEAKER_04So you were up against this, right? Let's talk about your journey. How did you manage that? And what kind of became your entry point to pharma?
SPEAKER_02So I actually did not start as an MSL. My first role within industry was as a project manager managing clinical trials. However, I was able to make that bridge, right? There are a lot of transferable skills being a pharmacist that going into a project management role, it's very easy, right? I mean, you have to have good communication skills, you have to have good organization skills, risk management, time management.
SPEAKER_02So once you just think about how you could transfer the skills that you already own, it's very easy to make the case while you are the right candidate for this role.
SPEAKER_04The skills you're talking about and the role you were in, what role were you in right before you joined a pharma company?
SPEAKER_02I was a medication therapy management uh pharmacist. So that role consists of engaging with patients, making sure that their medications are adequate, that there's no duplication of therapy, there's no polypharmacy, and make interventions on their behalf with their physicians.
SPEAKER_04I think what's important that you shared was this idea of maybe taking a step back and saying, okay, these are the requirements for the job from a skills perspective. How do I look at what I'm already doing on a day-to-day and translate that into something that makes sense for a hiring manager and honestly puts you in a job that you think you're going to be good at, right? Because that's the ultimate goal is to get a foot in the door, have it be successful. And then that opens up all sorts of options. So when you were, I want to get like really specific, right? Because somebody might be in this position right now.
SPEAKER_04You're taking the job description and putting it on the screen and mapping out what you're doing to that. How are you actually doing this?
SPEAKER_02Yeah, actually, it's funny you mentioned that because that's actually what I did, right? I pull up the job description and I started sorting out different scenarios or looking at my current role at the time and seeing how I could make the case for that. How could I be a great asset for that company? How does my skills sort of transfer over? I think it's important you have to really make the case. But for someone like myself who was a pharmacist who had, I would say, a great knowledge base of the science, the technical piece was the one that they were looking for that I was able to bridge with my skills that I had gathered in my other previous jobs as a community and as a MTM pharmacist.
SPEAKER_04I love that. I think it was kind of a mindset shift, right? That you're talking about. Um, and I think it's really cool to say, I know I can do this. And really, what it is is I have to create the business case for why hiring Emmett is a good idea. But it's not really that much of a stretch when you put it out like that. I mean, what you were describing in your role working with patients seems incredibly detail-oriented, seems incredibly scientific, right? And complex.
SPEAKER_04And so translating that over to another role clearly is possible because you had that conversation. So then what did you find once you were in there? That was not your end goal. Your end goal was not to be in the project manager space. Your end goal was to become an MSL. So describe what happened next.
SPEAKER_02I would say that the most challenging part of the role was just getting accustomed to all the farmer jargon, not something that you could pick up a book and study, right? It's actually on-the-job learning. I enjoyed the role in terms of I got the opportunity to participate in sort of the trial designs when they were sort of building those projects, but it was very operational, which for me, I wanted to get closer and closer to the science.
SPEAKER_02However, being an MSL, right, requires you to have knowledge of operations because you need to understand when you're talking to a physician timelines. Uh, if they want to participate in that clinical trial, right? You need to understand what are the requirements for that physician to partake in a clinical trial, right? Because not all physicians can participate, right? They have to have the right infrastructure, the right regulatory documents, and not all of them have that. So it's important for you to know the operational piece as well as understand the science of the molecule you're supporting.
SPEAKER_04Then we'll turn to Paul Howe. Paul's the chief operations officer at Protega Pharmaceuticals. He'll shed light on the opioid crisis, explain how a significant percentage of prescription opioids end up with someone they weren't intended for, and how new technology can help educate patients and mitigate risk. I think this is a great story, and it kind of helps us keep in mind that the work we do ultimately can have major impact on both individual patients and public health.
SPEAKER_04And so this is why this is such an interesting conversation to me, because as you sort of alluded to in your introduction, right, it's a job, it's a company, but it's also big impact on society. And, you know, I won't get into many people know, right, people that have dealt with this, and a lot of people got into addiction through seemingly benign ways. So I'm just curious, like, what do we know about common pathways to addiction and opioid dependence and all that right now?
SPEAKER_03It's interesting because as I got into this and didn't realize that 54% of the prescription opioids out there end up with a family, friend, somebody they weren't intended for over time. A lot of times it sits in the medicine cabinet, so to speak, a drawer somewhere, and a teenager picks it up, and that's where the initial contact starts. And the physicians, the medical community is well aware of the fact that the escalation is very quick. So unfortunately, when somebody does start to take oral opioid, and again, it's it's unfortunately still one of the biggest drug dealers in the United States, the biggest, is really the prescription medication that's left unattended and then it's taken.
SPEAKER_03So that's why the doctors know we're trying to stop that escalation in the case of Roxybond and our product. So the patient doesn't have that when they go from oral to crushing and inhaling or smoking or injecting, they're usually six months later on illicit fentanyl. And I know the big focus right now in the United States is on how to stop the illicit fentanyl coming through the borders, the cartel, what they're doing, et cetera. But we're also in the front part of this to stop that escalation where people do get addicted. We have a real opportunity to shut that down.
SPEAKER_03And that's what we're working on up front. And then with the technology we'll get into, I know as well, John, but we're going to be able to kind of do risk mitigation or risk stratification for the medical community and for patients.
SPEAKER_04I mean, that old piece is also interesting to me because I've had knee surgeries, right? ACL repair, and you leave with that with a prescription for some type of oxy, something, right? And then you're sitting there and you're like, well, I am in pain and I would like to not be in pain anymore, and I'd like to be able to get some sleep and uh and all of that type of stuff. But you hear all these horror stories of people, professional athletes, all the time, right? It started out with my knee surgery and then it escalated.
SPEAKER_04So maybe we could talk about a little bit about the education piece now, right? Because I think feel like from a patient's perspective, even a patient that works with pharmaceutical companies, it's really unclear. Like, should I just follow my doctor's directions? Or is that a problem or what?
SPEAKER_03What do I do? Exactly. And I think that you know, the medical board, the AMA, has certain criteria to help patients titrate down off medications and all. But if there's not the education piece there, and many of the physicians, especially in pain community, are so overwhelmed with the number of patients coming into their practice simply because other physicians and other practices, whether it's primary care, family medicine, et cetera, they don't want to treat patients with chronic pain anymore because of all the risk that's associated with it, unfortunately, due to things that have happened in the past.
SPEAKER_03So they transfer the patients into the chronic physicians and they're overwhelmed. They don't have time to really do all the education that they'd like to do. And that's where technology steps in. That's what we were able to identify is a group out of Stanford in the Stanford Pain Center that had this platform, a software, it's a SAS program software that was developed and has been developed and been fine-tuned and refined over the last eight years to where now it can be mass, you can offer it across the entire pain community.
SPEAKER_03And it's a way to do risk stratification and risk mitigation for physicians and patients, so that patients not only get treated with the ones that need to get treated, but also they get educated with some very, very excellent at great education on how you should titrate down. What are your symptoms you should look for? Your mu receptors, how they build up resistance potentially in your body. And so, therefore, you should try and go on a multimodal prescription plan and learn to titrate down. There's a lot of things, especially that titration piece for patients on how they really need to move away from the medication at some point and potentially if they still have chronic pain, try something different.
SPEAKER_03So there's all kinds of series of things as a patient that you're gonna get that education through technology now, through this platform that we offer, and I'm sure others at some point will offer as well, in addition to the abuse deterrent technology we have in the product, which really you heard what I said earlier about 54% go, it's taken that medication is is used by somebody it wasn't intended for. And so that's where this abuse deterrent technology works more so a lot of times than the patient that really needs it. There are millions of patients, and I think I know I mentioned to you the first time that it went up from 2020 to 2023.
SPEAKER_03It went from 20% of the US population had chronic pain to now 20 24.4%. So we're pushing one in four Americans have some form of chronic pain, which is defined as three months or longer of chronic pain a year. And so that is a growing issue in the United States. That's still the least expensive way to treat it. And the majority of patients do not get addicted to the medication is through an opioid. And the proper management of that opioid and the education is the back end that we're now offering that prior, because of just the sheer numbers of patients, doctors really didn't have an opportunity to educate at the level they'd like to.
SPEAKER_04If you've been enjoying the conversations here on Pharma Sessions, you should know they're made possible by the team at Excent. XSunt helps life sciences companies turn complex data into clear, actionable insight. For years, Excent has made complicated data sets simple to help commercial, medical, and operations teams map what's happening, predict what's next, and make stronger decisions faster. And now there's an added AI layer that makes everything work so much better. I was actually pretty jaded about some of the AI approaches I'd seen, but when Excent showed me theirs, I actually left my job to come work for them.
SPEAKER_04It's really awesome. So if you want to understand your market, your customers, or your performance with more clarity than ever, check out exunt.com. That's xsunt.com. All right, let's jump back into the episode. We'll also hear from Simeen Sayed, VP of Early Medical Pipeline at GSK. Simeen offers powerful take on improving collaboration, urging medical affairs teams to understand their commercial partners and to reframe commercialization as the process of getting innovations to patients at scale and at pace.
SPEAKER_04It's interesting. I think that this idea of silos and whatnot, it's not really specific to a Metafairs problem. It's sort of something that pharma is doing in general. Like, for example, I was just last week at this symposium called GPROS, which is all about labeling. And there were some people in the labeling regulatory space talking about why you actually do need to involve commercial way earlier when you're starting to think about your label, because that ends up being like the thing that goes out to the market and you need to design your clinical. So with the end in mind, right?
SPEAKER_04So that struck me as super familiar to what we're hearing with Metafares. So it's not, you know, for the Metafairs people out there, it's not, it's not you, right? These are there are some industry forces that are tailwinds that you're facing. If we could get maybe a little bit more specific, one of the things we talked about in the lead up to this was the idea of setting up a culture of collaboration. And I'm just wondering if there's anything you can share about where you've seen that done well, either by yourself, by others that you've come across, to give some people some maybe something a little more tangible to think about.
SPEAKER_00I guess, you know, having said all of the things that we've just said, I'm not saying that it's impossible or it's not possible to influence. Of course, you know, that's within all of our gifts. And I think one of the things that we have to recognize in whatever function we're in is the people that we're working with and we're collaborating with, what are they trying to achieve? Ultimately, I think as a function, we have to understand that we are a key part in the process of commercialization. And sometimes we find that an ugly word, but it's true.
SPEAKER_00And if you frame commercialization as the process of getting medicines or innovations to patients at scale and pace, then of course medical affairs has a role in that. And I think if you understand that's you have a role in that, then it's about actually what is it that we are trying to do as an organization? Who are the players? What are their roles and how do I fit in? And I think you start off by having that curiosity, right? You go into an organization, and certainly that's something I've I've seen work for myself and for others. You go in, you really try to understand how is this, what the organization is trying to do, what molecules have they got, where are they in their processes when it comes to Launch or pipeline or whatever, who have they got in place?
SPEAKER_00What are they trying to do? And then think about actually where is it that my role sits and how can I add value? And then having those conversations, building the trust, building the relationships with your cross-functional partners and peers, and then taking it from there. Because I think having those open, honest conversations, you're you're going to get much further. But it does start from understanding their perspective first and not coming in with a sort of, well, I'm medical affairs and this is my job. It does come with kind of going in, understanding the layer of the land, and then really figuring out the value we can add and articulating it.
SPEAKER_00And it's not too dissimilar to a process I'm going through at this moment. We've got a great medical affairs team. Uh, we're working in the early space and there's a lot of value being added. But, you know, sometimes it's about understanding what the various players want and how do we then showcase what we can do and articulate that.
SPEAKER_04There's a lot there. So let me just ask a couple of questions on that. I really like this idea of changing the mindset around how you engage with commercial, right? Where what you said, I think was commercial is getting medicines to patients at pace and at scale. And that's very different than like maximizing shareholder value or increasing revenues. But that's ultimately what it is, right? You're make working on medicines and they don't do any good if they're sitting on the shelf, right? They need to get into people's bodies. I guess my question is, and then what you described was kind of almost like take a step back and do some strategic work and some planning and some mapping of where you can bring value to the organization and work within your particular organization.
SPEAKER_04Do companies typically give space to take that time and do that work, or is that something you have to carve out for yourself?
SPEAKER_00I think again it varies. It depends on the, you know, so I've certainly worked in organizations where there was sort of the empowerment was given. And the expectation, to be fair, was actually you're part of this machine, go forth and figure out how your team are gonna add value to what we're trying to do here. But then there are times where you are literally just sort of, I mean, I think I did a LinkedIn post where people are just sort of drowning with stuff and it's then hard to know, kind of know where can I kind of pop my head up and have that strategic lens. But then that does become, if you're a senior medical leader, then that is on you to try and make that space to make it happen.
SPEAKER_00And it's not easy. I'm not going to pretend, oh yeah, it's just easy, just do this and you're done. It does take sort of a bit of bravery. And, you know, you might not be, you know, you might rub people up the wrong way, but ultimately, if your aim is to improve what you believe is right for the organization and you can speak to the people around you and they see that too, then that should help you on your way. But you're right, you have to create that space first in some places, and it's that's not always easy. So I'm not going to pretend it is.
SPEAKER_00My heart goes out to people who are trying, and it's probably a controversial thing to say, but you know, sometimes organizations aren't ready for future, they're the current, they're not ready for the type of medical affairs that some of us believe we can add, and maybe that's not the right place for you. Maybe you need to be in an organization where they see the value and you are then empowered to go forth and deliver. But there's no one size fits all. Every organization has different approaches, different cultures, different ways of working. So I think it's really up to you as an individual as to how you can either try and influence, figure out a path, and if not, then figure out other options.
SPEAKER_04And finally, Jennifer Mohawk, Executive Director of Medical Affairs at APAG Therapeutics. We'll get practical about work-life balance. I think this is kind of a fun way to end, but Jennifer shares her personal routine for decompressing after a workday at home to ensure she can transition effectively from her professional to her family life. I think that's something that we can all spend a little bit of time on. I hope you enjoy. I kind of have designed my whole career around work-life balance, to be completely honest, right?
SPEAKER_04And but what's really interesting is I feel like so I've I've been working from home since maybe like 2013 or so, sometime around then, maybe a little earlier than that. And some people have this concept of, you know, you're at home, you're slacking off, whatever, people people don't trust it, right? And there's this whole return to office push. And I have had completely the opposite feelings where when I go back to an office and I'm like, how does anybody get anything done with people coming through and and interrupting?
SPEAKER_04So from my perspective, I think it's totally a good thing to prioritize work-life balance because that means when you're sitting at your laptop, you're working and you're doing your thing and you're productive. And if you need to go out and pick up your kid at the end of the day, that's okay too, because you've already done like twice as much as somebody who was in the office would have done anyway.
SPEAKER_01For sure. And I think there's also the risk when you work from home that work time bleeds into what normally would be more protected home time.
SPEAKER_04Let's talk about that. So, how do you set sort of, I'm assuming you're working from home, because you said you've been working out of your house. When did you, when did you start doing that?
SPEAKER_01So, as an MSL, I've always been working from home to some extent. So for almost 10 years now, that's been a big part of what I've done. Always had a home office. But then when I pivoted to more of an in-house role, it was a lot more time, I'd say, in the house as opposed to on the road. The travel is still significant, but it's in a much different way than it was when I was an MSM.
SPEAKER_04Absolutely. And that was that was my experience as well, kind of on the vendor side is pre-COVID, I was with clients two or three days a week. And then there was a period of time where it was just me, myself, and I and the four walls closing in on me. How do you structure your day to set up those boundaries and you know, manage your priorities?
SPEAKER_01I know a lot of people like very, very formal boundaries, but for me, flexibility, and especially in my role, I think flexibility is more important than the clear boundaries. I do take time at the end of the day. So before I transition to going and making dinner or whatever it is back with my family, I found I need a little bit of time to kind of decompress, just process my workday. That used to be a commute, right? You would have that time between work and home. So if I don't take just a few minutes at the end of the day to set myself back up for home and putting my mom hat on.
SPEAKER_01So clear bias. I have a child, which colors a lot of these views. But my family doesn't like me very much if I don't take those few minutes to really kind of process and get back to home mode.
SPEAKER_04That was probably one of the things I struggled most with, right? From going from working from home without children to working from home with children, where they want you to be present and you want to be present for them. And so it is really tricky to like hang up on the Zoom meeting and then 30 seconds later you're you're in the thick of it, and you most likely still have thoughts or follow-ups, or I guess, do you have a routine or how do you actually take that time for yourself? What do you do in that time?
SPEAKER_01At the end of the day, and sometimes I go back to work after dinner, after the things, like, and I make it very clear to my family like, look, I have to go gonna take some time and do these things, you know, different than just a one-off email. But if I really need to sit down and focus. And so at the end of my work day, before I go transition to dinner time or driving to the clubs and the sports time, I go through my to-do list from that day, see what needs to be carried over to the next day. I kind of set up my agenda for tomorrow.
SPEAKER_01And that helps me get some of those thoughts out. Like what are the things that are hanging that I need to remember to do tomorrow? So I literally write them all out on my to-do list for the next day, sketch out that schedule, and then take a few minutes to just sit and see what other thoughts come. And it gives me just a little bit of decompression time.
SPEAKER_04That's really nice. Yeah, the writing, actually, physically writing things down is so to me, that is the secret of at the end of the day. It's like you can just trust your to-do list. And that's a wrap on today's episode of Pharma Sessions with me, Jonathan Kaske. If you enjoyed today's conversation, don't forget to hit follow or subscribe and share it with someone else in the pharma world who might need to hear it. For more on pharma trends, career growth, and business strategies, connect with me, Jonathan Kaske, on LinkedIn.
Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...
In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...
Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...
What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...
What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...